FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer
S Annett, G Moore, A Short, A Marshall… - British Journal of …, 2020 - nature.com
Background ALM201 is a therapeutic peptide derived from FKBPL that has previously
undergone preclinical and clinical development for oncology indications and has completed …
undergone preclinical and clinical development for oncology indications and has completed …
[HTML][HTML] FKBP51 decreases cell proliferation and increases progestin sensitivity of human endometrial adenocarcinomas by inhibiting Akt
J Dong, Y Jiao, W Mu, B Lu, M Wei, L Sun, S Hu… - Oncotarget, 2017 - ncbi.nlm.nih.gov
In this study, we investigated the role of FK506 binding protein 51 (FKBP51) in human
endometrial adenocarcinoma progression. Immunohistochemical analysis showed …
endometrial adenocarcinoma progression. Immunohistochemical analysis showed …
Loss of expression of antiangiogenic protein FKBPL in endometrioid endometrial carcinoma: implications for clinical practice
DD Obradović, NM Milić, N Miladinović, L McClements… - Medicina, 2022 - mdpi.com
Background and Objectives: FK506 binding protein like (FKBPL) is a member of the
immunophilin family, with anti-angiogenic effects capable of inhibiting the migration of …
immunophilin family, with anti-angiogenic effects capable of inhibiting the migration of …
FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism
A Valentine, M O'Rourke, A Yakkundi… - Clinical Cancer …, 2011 - AACR
Purpose: Antiangiogenic therapies can be an important adjunct to the management of many
malignancies. Here we investigated a novel protein, FKBPL, and peptide derivative for their …
malignancies. Here we investigated a novel protein, FKBPL, and peptide derivative for their …
The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway
A Yakkundi, L McCallum, A O'Kane, H Dyer… - PloS one, 2013 - journals.plos.org
FK506 binding protein-like (FKBPL) and its peptide derivatives exert potent anti-angiogenic
activity in vitro and in vivo and control tumour growth in xenograft models, when …
activity in vitro and in vivo and control tumour growth in xenograft models, when …
FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4
L McClements, S Annett, A Yakkundi, M O'Rourke… - BMC cancer, 2019 - Springer
Background Optimising breast cancer treatment remains a challenge. Resistance to therapy
is a major problem in both ER-and ER+ breast cancer. Tumour recurrence after …
is a major problem in both ER-and ER+ breast cancer. Tumour recurrence after …
FKBP10/FKBP65 expression in high-grade ovarian serous carcinoma and its association with patient outcome
MCJ Quinn, PM Wojnarowicz… - International …, 2013 - spandidos-publications.com
The frequent loss of chromosome 17 in epithelial ovarian carcinomas (EOC), particularly
high-grade serous carcinomas (HGSC), has been attributed to the disruption of TP53 (at …
high-grade serous carcinomas (HGSC), has been attributed to the disruption of TP53 (at …
[HTML][HTML] RNAi-mediated downregulation of FKBP14 suppresses the growth of human ovarian cancer cells
M Lu, Y Miao, L Qi, M Bai, J Zhang, Y Feng - Oncology research, 2016 - ncbi.nlm.nih.gov
FKBP14 belongs to the family of FK506-binding proteins (FKBPs). Altered expression of
FKBPs has been reported in several malignancies. This study aimed to reveal the …
FKBPs has been reported in several malignancies. This study aimed to reveal the …
Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway
L McClements, A Yakkundi, A Papaspyropoulos… - Clinical cancer …, 2013 - AACR
Purpose: FK506-binding protein like (FKBPL) and its peptide derivative, AD-01, have
already shown tumor growth inhibition and CD44-dependent antiangiogenic activity. Here …
already shown tumor growth inhibition and CD44-dependent antiangiogenic activity. Here …
KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
M De Donato, G Babini, S Mozzetti, M Buttarelli… - Journal of Experimental …, 2020 - Springer
Background In spite of great progress in the surgical and clinical management, until now no
significant improvement in overall survival of High-Grade Serous Ovarian Cancer (HGSOC) …
significant improvement in overall survival of High-Grade Serous Ovarian Cancer (HGSOC) …